(Q72805217)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

title

A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

main subject

phase II clinical trial

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

author name string

R B Weiss

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

B L Peterson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

S M Browning

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

D B Duggan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

C A Schiffer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

29 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

page(s)

41-43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00873234

29 October 2019

exact match

0 references

cites work

Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting

1 reference

12 December 2020

Hypersensitivity reactions from taxol

1 reference

12 December 2020

Multiple myeloma. An update on diagnosis and management

1 reference

12 December 2020

A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group Study

1 reference

12 December 2020

Management of refractory myeloma: a review

1 reference

12 December 2020

Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide

1 reference

12 December 2020

Phase II study of didemnin B in advanced colorectal cancer

1 reference

12 December 2020

Didemnins and tunichlorin: novel natural products from the marine tunicate Trididemnum solidum

1 reference

12 December 2020

Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00873234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7960604%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference